The U.S. Federal Trade Commission has reportedly reached a deal with pharmaceutical company Amgen that will both allow the drug maker to acquire Horizon Therapeutics and avoid trial.
The FTC previously filed an anti-competition suit against the potential merger in May.
According to a FTC press release, Amgen will be allowed to complete the $27.8 billion deal under certain stipulations.
The merger is expected to be completed at some point later this year.
